DUBLIN--(BUSINESS WIRE)--The "Genomics Market Size, Share & Trends Analysis Report by Application and Technology (Functional Genomics, Pathway Analysis), by Deliverables (Products, Services), by End Use, by Region, and Segment Forecasts, 2020 - 2027" report has been added to ResearchAndMarkets.com's offering.
The global genomics market size is expected to reach USD 31.1 billion by 2027, registering a CAGR of 7.7% over the forecast period according to this report.
Significant changes in disease management processes along with advancements in genomics and personalized medicine are expected to propel the market.
Increasing pool of market innovators such as 23andMe, Oxford Nanopore Technologies, and Veritas Genetics that have launched breakthrough genomic technologies in recent years are also contributing toward market development. 23andMe has expertise in developing direct-to-consumer genomic tests targeted toward disease prognosis and has recently received FDA approval for its commercialization.
MinION - a trademark sequencing device of Oxford Nanopore Technologies, is witnessing significant traction owing to its ability to sequence any fragment length of DNA in real time. On the other hand, Veritas Genetics offers an affordable solution for a complete readout of the genomic sequence.
Earlier procured only by doctors, these tests can now be taken by anyone curious about their DNA and costs approximately USD 1,000. The company has also begun the commercialization of this technique for newborn's genomic sequencing applications in China in 2017.
Further key findings from the report suggest:
- The consumables and reagents deliverable segment is expected to register highest growth rate owing to high costs associated with specific essential reagents along with high volume requirement
- The computational services deliverable segment is set to expand at a considerable CAGR from 2020 - 2027 owing to the increasing demand for computational sequence alignment and analysis among molecular biologists
- Development of predictive biomarkers targeted toward diagnosis and monitoring and substantial investments by biotechnology and pharmaceutical companies have contributed significantly to the revenue generated by the biomarker discovery application segment in 2019
- Asia Pacific is a potentially lucrative market for genomics and is anticipated to expand at the highest CAGR of 9.1%
Key Topics Covered:
1. Research Methodology
2. Executive Summary
3. Industry Outlook
3.1 Penetration & Growth Prospects Mapping
3.2 Trend Analysis
3.2.1 Application trends
3.2.2 Product trends
3.2.3 End-use trends
3.2.4 Regional trends
3.3 Genomics - Market Dynamics
3.3.1 Market driver analysis
22.214.171.124 Growing integration of genomics data into clinical workflows
126.96.36.199.1 More targeted and personalized healthcare
188.8.131.52.2 Growth of newborn genetic screening programs
184.108.40.206.3 Advancements in noninvasive cancer screening
220.127.116.11.4 Military genomics
18.104.22.168 Technological advances to facilitate genomic R&D
22.214.171.124.1 Emergence of advanced genome editing techniques
126.96.36.199.2 Integration of new data streams
188.8.131.52.3 RNA biology
184.108.40.206.4 Single cell biology
220.127.116.11 Rising adoption of direct to consumer genomics
18.104.22.168 Success of genetic tools in agrigenomics
22.214.171.124 Increasing participation of different companies
126.96.36.199 Increase in government role and funding in genomics
3.3.2 Market restraint analysis
188.8.131.52 Issues regarding intellectual property protection, data management, and public policies
184.108.40.206 Dearth of skilled personnel
3.4 Opportunity Analysis
3.5 Industry Analysis - Porter's
3.6 RegulatoryLandscape: Genomics- SWOT by PEST Analysis
3.7 Company Market Share Analysis
3.8 Competitive Landscape
Chapter 4 Genomics Market Categorization: Deliverable Outlook
4.1 Genomics Market Share By Deliverable Outlook, 2016 to 2027
4.2 Products Market, 2016 to 2027
4.2.1 Products market revenue (USD Million), by North America
4.2.2 Products market revenue (USD Million), by Europe
4.2.3 Products market revenue (USD Million), by Asia-Pacific
4.2.4 Products market revenue (USD Million), by Latin America
4.2.5 Products market revenue (USD Million), by Middle-East & Africa
4.2.6 Instruments & software market, 2016 to 2027 USD Million
4.2.7 Consumables & Reagents, 2016 to 2027 USD Million
4.3 Services Market, 2016 to 2027
4.3.1 Services market revenue (USD Million), by North America
4.3.2 Services market revenue (USD Million), by Europe
4.3.3 Services market revenue (USD Million), by Asia-Pacific
4.3.4 Services market revenue (USD Million), by Latin America
4.3.5 Services market revenue (USD Million), by Middle-East & Africa
4.3.6 Core genomic services, 2016 to 2027
4.3.7 NGS-based services, 2016 to 2027
4.3.8 Biomarker translation services, 2016 to 2027
4.3.9 Computational services, 2016 to 2027
4.3.10 Other services, 2016 to 2027
- Thermo Fisher Scientific, Inc.
- Life Technologies Corp.
- Affymetrix, Inc.
- Applied Biosystems
- Agilent Technologies
- Complete Genomics Incorporated
- Bio-Rad Laboratories, Inc.
- Beckman Coulter, Inc.
- Hoffmann-La Roche Ltd.
- 454 Life Sciences (Roche Diagnostics Corporation)
- Genentech, Inc.
- Ventana Medical Systems, Inc.
- GE Healthcare
- Illumina, Inc.
- Oxford Nanopore Technologies
- Pacific Biosciences of California, Inc.
- Quest Diagnostics Incorporated
- Foundation Medicine, Inc.
- Myriad Genetics, Inc.
- Eppendorf AG
- Eurofins Scientific
- Color Genomics, Inc.
- 23andMe, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/or3lsh